Podcasts about 340b

Pharmacy buyers play a critical role in keeping hospitals running—and their partnership with a GPO can make all the difference. In this episode of Verified Rx, Jackie Stokes sits down with Theresa Brown and Michelle Crump, two powerhouse pharmacy buyers and members of Vizient's Pharmacy Technician Committee, to talk about the tools, programs, and peer networks that help them thrive in their roles. From leveraging pharmacy analytics to navigating shortages, maximizing NovaPlus value, and strengthening buyer-to-buyer collaboration, this episode is packed with insights to help pharmacy teams work smarter, save money, and support better patient care.   Guest speakers:  Theresa Brown National Pharmacy Purchasing Specialist Prospect Medical Holdings   Michelle Crump, ASBA, CPhT National Certified Pharmacy Technician Buyer Pharmacy Host: Jackie Stokes Program Services Manager Center for Pharmacy Practice Excellence (CPPE) Vizient   Show Notes: [00:48] — Guest Introductions Theresa National pharmacy purchasing specialist Background: inventory control, home infusion startup, pharmacy technician educator [01:14] — Michelle Nationally certified pharmacy technician since 2016 Pharmacy buyer at a small independent county critical access hospital Transitioned from accounting into pharmacy purchasing   [01:26] — The Role of Vizient in Supporting Pharmacy Buyers Theresa: Biggest benefit: relationship with pharmacy executive & sourcing team Uses Pharmacy Analytics (formerly VSAP) to evaluate spend and inventory control across 63 facilities   [02:16] — How Pharmacy Analytics Supports Buyers Theresa: Data mining on spend increases/decreases Tracks product returns Identifies sharing opportunities to prevent waste [02:59] — Michelle's Experience Analytics helps mitigate waste Collaboration with other buyers has been essential — especially for someone new to the buyer role Learns navigation of Vizient systems and how to work with the local GPO Peer support helps demystify a “diverse and complex” buyer role   [04:02] — Value of the Vizient Pharmacy Technician Committee Provides national peer networking Helps buyers learn from subject matter experts Even highly experienced buyers (35+ years) learn from every call   [04:41] — Vizient Programs: NovaPlus, NES, Forum Calls, Hot Info Bimonthly Forum Calls Provide regulatory updates Help expand buyer knowledge in real time Hot Info Weekly Updates Keeps users informed on inventory, shortages, spend impacts [05:31] — Michelle on Program Impact Calls and shared expertise were critical when she was new NovaPlus program especially valuable in critical access settings   [06:32] — Deep Dive: How the NovaPlus Program Works Michelle explains: NovaPlus (Y-label) aligns with manufacturer-labeled products (M-label) Quarterly rebates provide significant savings Critical access hospitals benefit via 340B optimizer software that extracts outpatient utilization to qualify for discounted M-label purchasing Can result in “significant savings” depending on contract structure   [08:38] — What If NovaPlus Pricing Isn't the Best Price? Michelle: Buyer's responsibility to identify price discrepancies Communicates with Vizient representative to reassess contracting needs Often resolved through rebates or future price adjustments [09:30] — Theresa: Price challenges taken seriously Many result in price reductions visible in Hot Info the next week Demonstrates importance of strong GPO relationships   [10:07] — Understanding NES: NovaPlus Enhanced Supply Theresa: Her hospitals are exploring NES participation Requires 90% compliance (higher than standard 80%) Benefits include prioritized product access during shortages Critical when national backorders exceed 200+ items Ensures better patient care continuity   [11:34] — Supply Assurance & Mitigation Strategies Michelle: During the North Carolina hurricane, Vizient's mitigation strategy was “imperative” Vizient engaged Baxter directly to resolve critical fluid shortages Small hospitals especially reliant on support in crisis situations [12:36] — Theresa: Shortage team provides substitution guidance and clinical appropriateness information Vizient recommendations support discussions with local clinical teams Crucial during COVID start date — her first day in national role   [13:23] — Continuing Education (CE) Programs Theresa: Vizient CE programs help maintain technician licensure Webinars are interactive, engaging, and more informative than generic CE resources   [14:07] — Networking and Pharmacy Aggregation Groups (PAGs) Theresa: PAGs offer cost savings and peer collaboration Ability to share information and bring value back to her own network [14:44] — Michelle's Example of System-to-System Collaboration Shared compounded syringes (from a 503B facility) with another hospital to prevent waste Highlights real-world benefits of PAG networking   [15:52] — Addressing National Challenges Together Theresa: PAG roundtables help uncover shared struggles (e.g., DSCSA serialization issues) Members provide actionable advice on what's working in their systems Reinforces “we're all in the same boat”   [16:50] — Supporting and Elevating Pharmacy Technicians Jackie's goal: Support technicians and recognize the value they bring Committee exists to uplift and empower pharmacy buyers/techs [17:05] — Michelle: Worked with leadership to create a tiered technician level system Helps techs gain skills, feel valued, and earn raises Improves career satisfaction and retention   [17:46] — Closing Reflections Theresa: Being part of Vizient is “an honor and a privilege” Values shared knowledge and strong relationships [18:00] — Michelle: Gratitude for collaboration and guidance over the years Vizient connections were vital for adapting to the buyer role   VerifiedRx Listener Feedback Survey: We would love to hear from you - Please click here   Subscribe Today! Apple Podcasts Spotify YouTube RSS Feed

In this special 2025 U.S. Policy Highlights edition of the Vital Health Podcast, we look back at our most important discussions on Most Favored Nation (MFN) drug pricing and its knock-on effects for jobs, state budgets, and the generic supply chain. Over the past year, proposals to link U.S. prices to those in other countries have collided with inflation pressures, tariff debates, and reshoring efforts, creating new uncertainty for manufacturers, payers, and policymakers. In an environment where expectations about future returns are shifting, and the rules of the game are still being defined, this episode is designed as a year-end guide to what MFN-style policies could mean in practice and how to think about the tradeoffs. Throughout 2025, we our research on MFN-style reference pricing with a series of podcast episodes where host Duane Schulthess sat down with leaders across the generic, distribution, and policy landscape. In this highlights episode, we revisit several of those conversations: Kirsten Axelsen: Part D Shift, IRA Penalties, and Access Risks Patrick Kelly: Inside the Generic Supply Chain Squeeze John Murphy: Generics, Biosimilars, and U.S. Policy VT’s Grumpies (Harry Bowen, Joe Hammang) Talk MFN Key Topics: MFN Mechanics Explained: How tying U.S. prices to the lowest GDP-adjusted price in a reference basket translates into steep cuts for top-spend medicines in Medicare Parts B and D and shapes expectations across commercial and Medicaid contracts. Jobs, Earnings, & State Budgets: What our modeling suggests about potential impacts on employment, earnings, and tax revenue under MFN-style reference pricing, and how those effects concentrate in R&D-intensive regions and manufacturing hubs. Spillovers Into Medicaid, 340B, & ASP: Why MFN in Medicare does not stay in Medicare, how Medicaid best price and 340B ceilings pull discounts across programs, and what lower ASP add-ons could mean for hospital and community oncology margins. Generics, Shortages, & Tariffs: How razor-thin margins for sterile injectables and generic manufacturers interact with purchaser consolidation, tariff shocks, and price referencing, raising the risk of exits, inventory write-downs, and persistent shortages. Global Competition & Offshoring: How aggressive reference pricing can accelerate shifts in trials, licensing, and high-value manufacturing to countries that offer more predictable returns, and what that implies for long-run U.S. competitiveness. Alternatives To MFN: Ideas from our guests on value-based approaches, targeted incentives, and other tools that can improve affordability without hollowing out domestic capacity, innovation, and resilience in the generic and biosimilar supply chain. Opinions expressed are those of the speakers.See omnystudio.com/listener for privacy information.

In this episode, Greg and Rob recap key developments in the 340B space from 2025.  They'll discuss the flurry of activity in recent months related to 340B rebates, project the impact of the OBBB on DSH hospitals, share insights from HRSA audit trends over the last year, and offer commentary on one of the few high points for 340B providers this year – state legislative activity. Also, Rob offers a heartfelt pep talk for 340B folks at the end of the episode – so make sure you listen through to the end! Medi-Cal Provider Guidance on 340B Rebates:  https://mcweb.apps.prd.cammis.medi-cal.ca.gov/news/33779 Email us at 340BUnscripted@spendmend.com with your questions and comments!

340B Insight wants to make our podcast the best it can be. To help us succeed, we'd like to hear your thoughts. Please take just a few minutes to complete our listener survey, and we will enter you in a drawing to win a $100 gift card! To participate, please go to 340bpodcast.org/survey.With monumental movement on 340B rebates, changes in Medicare and Medicaid payments, and evolving audit priorities, 2025 has been a transformative year in the world of 340B. We sit down with 340B Health Senior Manager of Policy and Compliance Rebecca Swartz to chronicle some of the biggest developments of such an eventful year and forecast what to expect in 2026.Rebates Take ShapeSwartz says 2025 will go down as the year that a rebate model shifted from a hypothetical approach pushed by drugmakers into a fully developed model with implementation criteria. The Health Resources & Services Administration (HRSA) approved plans for 340B rebate models set to take effect in January for nine of 10 drugs subject to the 2026 Medicare maximum fair prices. Rebates for the remaining drug on that list will kick in April 1. Swartz discusses how hospitals should prepare for this pilot program, which is set to upend decades of established 340B operations and impose intense financial and logistical burdens on safety-net hospitals nationwide.Medicaid, IRA Changes Set To Impact 340B HospitalsThis year also saw massive changes to Medicaid funding as well as Medicare pay changes under the implementation of the Inflation Reduction Act (IRA). Swartz says these developments are projected to shrink safety-net hospital margins even further. Renewed congressional focus is putting 340B in a high-profile spot, with potentially significant implications for the program and hospitals in the coming months.2026 Tips for HospitalsSwartz says she's identified two areas as more of a focus for HRSA audits this year: expanded scrutiny of offsite and on-site trial balances and the ways covered entities list shipping addresses. To prepare for possible shakeups in 2026, she recommends that covered entities begin and maintain cross-functional planning across departments and closely monitor denials, delays, and other costs from new rebate programs in addition to monitoring wholesale acquisition cost (WAC) changes and contract pharmacy developments.Resources340B Health Year-in-Review Webinar: 2025 Highlights and What's on the Horizon

The status quo is expensive, exhausting, and unsustainable—so we set out a practical playbook to do better in 2026. Nathan Kaufman shares ten no‑nonsense resolutions for health system leaders who want measurable outcomes, stronger teams, and smarter payer strategies without falling for vendor hype or wishful thinking.We get specific about capital discipline and why “mission” can't justify chronic losses that drain resources from services that actually improve patient care. We talk through what it takes to win the talent war by treating physicians as true partners, then dive into dyad leadership that cuts across supply chain, HR, and IT to remove friction and accelerate results. Culture becomes operational with real-time metrics, fast feedback loops, and leaders spending more time in the field and less time in meetings that signal low trust and unclear decisions.Payment strategy is front and center. We explain how to use 340B responsibly to close funding gaps, why some value-based schemes are a race to the bottom, and how to negotiate Medicare Advantage so contracts yield at least 100% of Medicare after accounting for administrative burden. Affordability demands that we take significant cost out by removing layers, standardizing clinical pathways, and focusing on core services rather than chasing panaceas like provider-owned health plans or sponsored “research” that flatters a product.If you're ready to lead with data, align teams, and make tough calls that protect patient access and quality, this conversation is your roadmap. Subscribe, share with a colleague who needs a dose of operational courage, and leave a review telling us which resolution you'll tackle first.Support the showEngage the conversation on Substack at The Common Bridge!

Sitting at the intersection of healthcare policy, hospital finance, and patient access, the 340B drug discount program is a hot button issues in the pharmacy space. The program is critically important to providers that serve high volumes of low income and vulnerable patient populations, but it's drawing increasing scrutiny.340B was established in 1992 as part of the Public Health Services Act to help providers stretch scarce resources, expand services, and improve access to care for those most in need. It does this by requiring pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at significant discounts to safety net hospitals and other covered entities – including federally qualified health centers (FQHCs), HIV clinics, homeless clinics and more. Covered entities are reimbursed for the full cost of the medication and use that margin to offset losses from caring for low‑income, uninsured, and underinsured patients. It's become a critical component to their operating budgets.The program has grown substantially since its inception, with increasing numbers of hospitals and entities participating. This expansion has led to questions about whether the program is being used as intended or stretched beyond its original purpose.Ted Slafsky – one of the nation's leading experts on 340B – joined Keith Figlioli for this episode of Healthcare is Hard to unpack this complex and critical program. For 22 years, Ted served as president and CEO of 340B Health, a Washington D.C.-based association of over 1400 hospitals nationwide participating in the 340B program. In 2020, he started 340B Report, the only news outlet in the country focused exclusively on the 340B program.Some of the topics Ted and Keith discussed include:Balancing oversight and operational efficiency. The 340B program faces growing calls for transparency and accountability, with proposals for more detailed reporting on how hospitals and clinics use the savings. While oversight is important to ensure compliance and integrity, Ted warns that excessive administrative requirements could overwhelm providers and divert resources away from patient care. The challenge is finding a balance that promotes trust without creating an operational burden.Dispelling Myths. One common misconception about 340B is that it's a direct patient discount program. Ted addressed this myth, explaining how the discount is intended for providers to give them more resources to reach and serve more patients. The other myth Ted addressed is how the program is described – mostly by the pharmaceutical industry – as a “markup scheme.” He doesn't think that's a fair depiction and explained that revenue from commercially insured patients is essential for offsetting the cost of treating uninsured and underinsured patients, making the program a lifeline for safety-net providers.An uncertain future. The 340B program faces significant uncertainty as policymakers consider major changes. Recent efforts to replace upfront drug discounts with a rebate model could strain the financial stability of small and rural providers, while federal proposals to cut Medicare Part B reimbursement add further pressure. At the same time, state legislatures are enacting a patchwork of laws to protect providers and restore contract pharmacy discounts, creating complexity across the country. Ted advises providers to not simply hope for the best. He urges hospitals and health centers to engage directly with lawmakers and their staff by inviting them to visit facilities where they can see the program's impact and its role in supporting vulnerable populations.To hear Ted and Keith discuss these topics and more, listen to this episode of Healthcare is Hard: A Podcast for Insiders.

In the final session of The Profit Playbook: Ending 2025 Like a Badass, Heather Haro is joined by Julie Crozier, RPh and Amanda Gaddy, RPh of Secure 340B to break down critical changes coming to 340B rebates and Medicare Fair Pricing (MFP) rebates in 2026. This session explains how overlapping rebates work, what changes on January 1, and what independent pharmacies must do now to protect cash flow, margins, and patient access.   **Show Notes:** 1. **Introduction** [0:00] 2. **Introduction of Secure 340B Experts** [3:27] 3. **Overview of 340B and MFP Rebates** [7:01] 4. **Detailed Explanation of Rebate Processes* [41:07] 5. **Impact of Wholesale Acquisition Cost (WAC) Decreases* [41:29] 6. **Q&A Session and Additional Clarifications* [43:48] 7. **Final Remarks and Contact Information* [46:11]     ----- #### **Becoming a Badass Pharmacy Owner Podcast is a Proud to be Apart of the Pharmacy Podcast Network**

As the 340B Rebate Model Pilot approaches, hospitals and health systems are preparing for one of the most significant shifts the program has faced in years. In this episode, Jim Jorgensen is joined by Kristin Fox-Smith, Managing Director, and Jerame Hill, Chief Strategy Officer at Visante, to break down what the new rebate model means for covered entities.   This conversation is especially important for hospital executives as the rebate model directly impacts cash flow, staffing needs, operational risk, and financial planning. The group discusses the real-world implications of HRSA's guidance, including increased data and reconciliation complexity, ongoing uncertainty as January 1 approaches, and the decisions leaders may soon face. Listeners will also hear practical insight on how to prepare now to reduce risk and protect organizational performance.

Advisory Board is here to do two things: tackle the toughest questions keeping healthcare leaders up at night, and push leaders' thinking on the questions they aren't asking – but should be. In 2025, we navigated a landscape of major shifts, from policy changes, the growing presence of AI, drug innovations, and more. As we head into 2026, we are keeping that momentum going to deliver the insights you need to stay ahead. That's why this week, hosts Rachel (Rae) Woods and Abby Burns pass the microphone to six Advisory Board researchers to preview their top questions and topics on our research agenda for the new year. They'll unpack what they're researching, why it matters, and why these topics deserve your attention. [1:30] Ty Aderhold on cutting through the AI hype [4:15] Monica Westhead on margin management and hospital efficiency [7:08] Sally Kim on cutting costs and scaling health plan operations [9:45] Sebastian Beckmann on prioritizing sustainable growth through smarter forecasting and analytics [14:08] Kaci Plattenburg on rethinking service line growth strategies [16:27] Chloe Bakst on navigating the pharmacy policy shakeup We're here to help: Read Advisory Board's 2026 research agenda The state of the industry: Key insights for 2026 249: What is 340B, and why is it in the hot seat 267: Care variation reduction: A $100B opportunity What's driving — or slowing — service line growth? 270: Service line snapshot: What every health leader needs to know 276: The AI gold rush is changing how humans (and clinicians) make decisions [Tools] Use Advisory Board tools to inform your strategy for growth, cost control, and more. We want to hear from you. What are your challenges? Where are you seeing opportunities? Email us at podcasts@advisory.com Learn about Advisory Board Research Membership. How the collaborative care model improves access to behavioral healthcare How We Approach Behavioral Health Integration | evolvedMD A transcript of this episode as well as more information and resources can be found on RadioAdvisory.advisory.com.

Send us a textFederally Qualified Health Centers (FQHCs) care for more than 30 million Americans, yet many people have never heard of them or understand how they stay afloat. A major piece of their financial survival is the 340B drug pricing program, which has quietly become one of the most important funding mechanisms in the safety net and it is under growing pressure.Scott Seidelmann, CEO of Nuvem, joins CareTalk hosts David E. Williams and John Driscoll to discuss how FQHCs serve underserved communities, why 340B has become essential to their operations, and what policy changes could make or break their ability to deliver care.

In this episode of Healthcare Americana, host Christopher Habig talks with neurosurgeon and healthcare policy leader Dr. Anthony DiGiorgio about the growing crisis around prior authorizations. They discuss how complicated approval processes delay urgent care, burden physicians, and put patients at risk. Dr. DiGiorgio explains why smarter, low-friction models such as gold-carding and stronger subspecialty board oversight could help rebuild trust between physicians and payers. The conversation also covers the 340B drug discount program, which Dr. DiGiorgio has testified about before Congress. He explains how a program originally designed to help low-income patients has become a major revenue source for large hospital systems and often increases costs for Medicaid, Medicare, and private insurance. Together, they offer a clear and accessible look at what is broken in these systems and what meaningful reform could achieve.More on Freedom Healthworks & FreedomDoc HealthSubscribe at https://healthcareamericana.com/More on Dr. Anthony DiGiorgioFollow Healthcare Americana: Instagram & LinkedIN

340B Insight wants to make our podcast the best it can be. To help us succeed, we'd like to hear your thoughts. Please take just a few minutes to complete our listener survey, and we will enter you in a drawing to win a $100 gift card! To participate, please go to 340bpodcast.org/survey.Some of the most consequential changes for 340B this year came not from Washington D.C., but from statehouses across the country. We speak with Tom O'Donnell, senior vice president of government relations at 340B Health, to recap some of the biggest changes on the state legislative level throughout this year and to preview what might come from the states in 2026.Seven States Enact New Reporting LawsThis year, Colorado, Hawaii, Idaho, Indiana, Ohio, Rhode Island, and Vermont have added new 340B reporting laws, increasing the list of states with such mandates to 10. O'Donnell says the first reporting requirements that Minnesota enacted in 2023 have influenced newer requirements in the other states. He notes hospitals' continuing concerns about the burdens and possible repercussions of focusing on several specific types of reporting data, including breakdowns by payer type and most frequently used drugs.Hybrid Bills Combine Protections With Reporting MandatesFive states that passed new 340B laws in 2025 did so with a twist. Colorado, Hawaii, Maine, Rhode Island, and Vermont passed combination bills with both contract pharmacy protections with new reporting mandates. O'Donnell says he's also concerned that statehouses are shoehorning in amendments to original statutes to ramp up concerning reporting requirements.Model Legislation Could Mean More Debate in 2026While Minnesota has served as a reference for reporting mandates for other states, model legislation from the American Legislative Exchange Council (ALEC) has created more opportunities for state legislators to push proposals that would limit or scrutinize 340B. O'Donnell says this reflects part of the latest efforts from drugmakers to take their 340B priorities to sympathetic lawmakers at the state level, and it underscores the importance of informing and supporting hospitals on how to push back against these bills.Resources:HRSA Approves Novartis's 340B Rebate Pilot ProposalState Policy & Advocacy Communications Resource Center

In this episode, Greg and Rob are joined by Katheryne Richardson of the Beacon team, to discuss frequently questions about the upcoming 340B rebate model.  They'll cover the differences between Beacon applications, commonly asked questions regarding data submission, and tips for covered entities to consider as the implementation date approaches. Come see us at Booth #1545 during this year's ASHP Midyear Clinical Meeting!

Rural Health News is a weekly segment of Rural Health Today, a podcast by Hillsdale Hospital. News sources for this episode: American Hospital Association, “AHA, other file suit to block unlawful 340B changes threatening patient care,” December 1, 2025, https://www.aha.org/news/headline/2025-12-01-aha-others-file-suit-block-unlawful-340b-changes-threatening-patient-care. Bridget Early, “Home health providers hit with Medicare pay cut,” December 1, 2025, https://www.modernhealthcare.com/politics-regulation/mh-medicare-home-health-pay-2026-cms/#, Modern Healthcare. Celli Horstman, Arnav Shah, “The State of Rural Primary Care in the United States,” November 17, 2025, https://www.commonwealthfund.org/publications/issue-briefs/2025/nov/state-rural-primary-care-united-states?mkt_tok=NzEwLVpMTC02NTEAAAGeOB9y6SbuBxye3wQ7igjy1BVe5GMJxaV9fCloFJmQfS-T6mbVfjH7QWw88rhSoHiy3G1b3YS0OFamdkSiphiBb7XyLWJP3BOoGozzQcWDe1J4qOk, The Commonwealth Fund. Erica Cerutti, “The state of rural primary care: 4 notes,” November 19, 2025, https://www.beckershospitalreview.com/quality/hospital-physician-relationships/the-state-of-rural-primary-care-4-notes/, Becker's Clinical Leadership. Rural Health Today is a production of Hillsdale Hospital in Hillsdale, Michigan and a member of the Health Podcast Network. Our host is JJ Hodshire, our producer is Kyrsten Newlon, and our audio engineer is Kenji Ulmer. Special thanks to our special guests for sharing their expertise on the show, and also to the Hillsdale Hospital marketing team. If you want to submit a question for us to answer on the podcast or learn more about Rural Health Today, visit ruralhealthtoday.com.

In this episode, ​​Laura Dyrda, Vice President and Editor-in-Chief at Becker's Healthcare, shares the top stories she is tracking, including the major 340B program shakeup and escalating workforce challenges.

Not gonna give much of an introduction here because this is a short bonus level set, but I did just wanna call everyone's attention to the "arms race" created by our status quo purchasing and selling of many things, pharmaceuticals included. For a full transcript of this episode, click here. If you enjoy this podcast, be sure to subscribe to the free weekly newsletter to be a member of the Relentless Tribe. For example, raise the list price of a drug to maximize rebates, because the higher the list, the bigger the discount you can give, which then exacerbates patient affordability because coinsurance is often based on list price. But then Pharma starts offering co-pay cards, which messes up the whole PBM (pharmacy benefit manager) plan to drive patients to their highest-rebate products (ie, the most profitable products). So then maximizers and accumulators enter the chat, and prior auths ramp up because plans start having to raise premiums after enough 340B drugs with high lists and no rebates, and then there's no cost containment and raise deductibles and around and around we go. Meanwhile, is this drug fundamentally worth the list price or even the net price? Is it an effective drug? What's the right price to be paying for this drug? Should be the operative question, right? Just like what's the quality and appropriateness of any medical service? Maybe we should just quit it and just pay for value. And with that, let me introduce Sarah Emond, CEO of ICER (Institute for Clinical and Economic Review), and I will let Sarah tell the rest of the story. Also mentioned in this episode are Institute for Clinical and Economic Review (ICER); Cora Opsahl; 32 BJ Health Fund; Payerset; Aventria Health Group; Dea Belazi, PharmD, MPH; and Tom Nash. For a list of healthcare industry acronyms and terms that may be unfamiliar to you, click here.   You can learn more at ICER.org and follow Sarah on LinkedIn.   Sarah K. Emond, MPP, is president and chief executive officer of the Institute for Clinical and Economic Review (ICER), a leading nonprofit health policy research organization, with 25 years of experience in the business and policy of healthcare. She joined ICER in 2009 as its first chief operating officer and third employee and has worked to grow the organization's approach, scope, and impact over the years. Prior to joining ICER, Sarah spent time as a communications consultant, with six years in the corporate communications and investor relations department at a commercial-stage biopharmaceutical company and several years with a healthcare communications firm. Sarah began her healthcare career in clinical research at Beth Israel Deaconess Medical Center in Boston. A graduate of the Heller School for Social Policy and Management at Brandeis University, Sarah holds a Master of Public Policy degree with a concentration in health policy. Sarah also received a bachelor's degree in biological sciences from Smith College. Sarah speaks frequently at national conferences on the topics of prescription drug pricing policy, comparative effectiveness research, and value-based healthcare.   02:28 What is ICER? 02:47 What does the Institute for Clinical and Economic Review do? 05:09 The importance of still showing up, even when others don't understand or disagree. 06:51 EP293 ("Game Theory Gone Wild") with Dea Belazi, PharmD, MPH. 09:04 Why it's important to think about population health and how our choices impact affordability for everyone.   You can learn more at ICER.org and follow Sarah on LinkedIn.   @sarahkemond discusses #ICER and the status quo of #pharmaceuticaldrug #pricing on our #healthcarepodcast. #healthcare #podcast #financialhealth #patientoutcomes #primarycare #digitalhealth #healthcareleadership #healthcaretransformation #healthcareinnovation   Recent past interviews: Click a guest's name for their latest RHV episode! Stacey Richter (INBW43), Olivia Ross (Take Two: EP240), John Quinn, Dr Sam Flanders and Shane Cerone (EP492), Elizabeth Mitchell (EP491), Shane Cerone and Dr Sam Flanders (Part 1), Dan Greenleaf (Part 2), Dan Greenleaf (Part 1), Mark Cuban and Cora Opsahl  

In this episode, Scott Becker highlights seven major healthcare developments, including Providence's transformation efforts, CHS's strategic shift, the growing role of pharmacy, legal challenges to 340B changes, and more.

In this episode, Greg and Rob catch up on some clarifications gained around the upcoming 340B rebate model, including purchasing requirements and developments with select chain retail pharmacies updating their policies. Additionally, they discuss the CMS CY2026 OPPS final rule that was just published, including potential implications for 340B hospitals. CMS Hospital Drug Acquisition Cost Survey Info: https://www.cms.gov/medicare/payment/prospective-payment-systems/hospital-outpatient-pps/outpatient-prospective-payment-system-opps-drug-acquisition-cost-survey Come see us at booth #1545 at the ASHP Clinical Midyear Meeting December 8-11 in Las Vegas!

In this special mini-episode, we invite listeners to help shape the future of the show and enter a drawing for a $100 gift card by participating in our first-ever listener survey. Since launching in May 2020, 340B Insight has released more than 125 episodes featuring conversations with hospital and health system leaders, policy experts, and operations specialists from across the country. Their insights have helped listeners stay informed on the latest developments in 340B and bring practical lessons back to their own organizations.As we plan the next phase of the podcast, we want to hear directly from our listeners. The brief survey asks what draws you to the show, the topics and guests you've found most valuable, and what you'd like us to explore in future episodes. Your input will help ensure the podcast continues to reflect the needs and interests of the 340B community.The survey takes only a few minutes to complete. You may submit your responses anonymously, or you can share your contact information to be entered into a drawing for a $100 gift card. Take the survey by visiting 340bpodcast.org/survey. Thank you for listening and sharing your thoughts!

Welcome to The ASHHRA Podcast! In this episode, hosts Bo Brabo and Luke Carignan sit down with Keith Sorgius, a dedicated hospital advisor at RxBenefits, to dive deep into the world of pharmacy benefits and cost management for hospitals and health systems. With a rich background in pharmacy analytics, PBM consulting, and 340B in-house pharmacy management, Keith Sorgius shares his practical insights on using data-driven strategies to identify savings opportunities and maximize the value of in-house pharmacy operations.Together, the trio explores the role of predictive analytics in pharmacy plan management, the critical relationship between HR and pharmacy teams, and the importance of transparent communication when rolling out new benefits strategies. You'll learn why benchmarks can be tricky to rely on, how leveraging your own hospital pharmacy can be a game-changer for costs and patient care, and best practices for getting buy-in from employees and their families.Whether you're in HR, pharmacy operations, or just passionate about controlling healthcare costs, this episode is packed with actionable advice and real-world stories to help you navigate the ever-evolving pharmacy benefits landscape. Let's get started! From Our Sponsors...Optimize Pharmacy Benefits with RxBenefitsElevate your employee benefits while managing costs. Did you know hospital employees fill 25% more prescriptions annually than other industries? Ensure cost-effective, high-quality pharmacy plans by leveraging your hospital's own pharmacies. Discover smarter strategies with RxBenefits.Learn More here - https://rxbene.fit/3ZaurZNStreamline HR Compliance with oneBADGEhealthcareSimplify screening, credentialing, and compliance for healthcare HR. oneBADGEhealthcare from ISB Global offers a tailored solution to keep your workforce compliant and efficient. Built for healthcare leaders, it's your all-in-one compliance tool.Get Started here - https://isbglobalservices.com/onebadgeunitedstates/ashhra/ Support the show

Dr. Robert Popovian is a pharmacist, and economist with a deep background in research and public policy. In this episode we have a nuanced discussion on policy impacting pharmacy including PBMs, President Trumps Most Favored Nation Executive Order, Rebates, and insurance premiums.    Links to resources referenced in discussion: • Pioneer Institute, 340B tool: https://pioneerinstitute.org/340babuse/ • Pioneer Institute, IRA tool: https://pioneerinstitute.org/the-inflation-reduction-act-ira-overview/ • Editorial regarding TrumpRX: https://www.linkedin.com/pulse/promise-trumprx-robert-popovian-vskne/?trackingId=dtiG1P%2B%2BSDq6adLfFeEbeg%3D%3D • Pioneer Institute, IRA report: https://pioneerinstitute.org/wp-content/uploads/Prescription-Drug-Price-Controls-06252025.pdf  • GHLF tool, Impact of Accumulators and Maximizers on Premiums: https://cutt.ly/Rr9Di7Vf • Conquest Advisors website: https://conquestadvisors.godaddysites.com/

340B Insight wants to make our podcast the best it can be. To help us succeed, we'd like to hear your thoughts. Please take just a few minutes to complete our listener survey, and we will enter you in a drawing to win a $100 gift card! To participate, please go to 340bpodcast.org/survey.The large and growing field of specialty pharmacy means new opportunities and challenges for ensuring patients receive the specialty drugs they need and stay on the therapies that might save their lives. St. Luke's Health System, based in Boise, Idaho, has approached this mission by embedding clinical pharmacists in the specialty pharmacy space and using 340B as a critical tool. We speak with Josh Weber, senior director of ambulatory retail and specialty pharmacy services at St. Luke's, to learn more.How Clinical Pharmacists Can Be a “Value Multiplier”Embedding clinical pharmacists in their specialty pharmacies improves operations in myriad ways. These pharmacists can take the burden off other providers by meeting with patients to go over their drug regimens, coordinating care, and running split-fill programs to reduce waste. At St. Luke's, the approach has improved patient adherence to medications and reduced the time between the specialty prescription and the patient having the medication in hand to less than 48 hours – far quicker than the industry standard.340B Savings Are Key to the InvestmentWeber says cost savings from 340B are critical in calculating how they embed resources into specialty pharmacy, noting that improving adherence and retention can increase 340B savings exponentially. These savings then can enable health systems such as St. Luke's to reinvest in their internal specialty pharmacies, provide more patient cost assistance and unreimbursed care, and ultimately shield themselves from headwinds such as drugmaker contract pharmacy restrictions.Embedding Pharmacists Depends on Hospital-Specific FactorsFor hospitals considering following the lead of St. Luke's Health System, Weber said a variety of factors such as patient volume, payer mix, and drug spend can call for a variety of service models and investment strategies. Harnessing data such as heat maps showing where patients are and which clinics they visit can inform how best to embed pharmacists and ultimately improve specialty pharmacy care for patients.Resources:Drugmakers Release 340B Rebate Pilot Program DescriptionsHRSA 340B Rebate Model Pilot ProgramBeacon Rebate Model Resources

This podcast will provide members with an update on federal and state action over the past 6 months on the 340B program. We'll talk through 340B policy shifts at the federal level and what's happening in the states. We'll also discuss where 340B advocacy goes from here.  The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of transformative events reshaping the landscape of healthcare, from strategic mergers and regulatory shifts to groundbreaking advancements in drug development.Let's begin with a monumental merger that signals a shift towards more integrated healthcare solutions. The $48.7 billion acquisition of Kenvue, a consumer health spinout from Johnson & Johnson, by Kimberly-Clark illustrates the growing convergence between consumer health products and traditional pharmaceuticals. This strategic move highlights a trend towards expanding product portfolios and enhancing distribution networks, aiming to better address comprehensive patient needs. Mergers like these could redefine how healthcare products are marketed and delivered, emphasizing holistic approaches to patient care.Turning to regulatory news, the resignation of Dr. George Tidmarsh from the FDA due to controversial communications has spotlighted the ongoing challenges within regulatory oversight. This incident underscores the delicate balance regulators must maintain in ensuring transparency while safeguarding sensitive information. Such developments are crucial as they directly affect public trust in drug approval processes and the industry's ability to navigate complex regulatory landscapes.In scientific advancements, Roche is making significant progress with its drug Gazyva for autoimmune diseases. Following FDA approval for lupus-related kidney disease, promising Phase 3 trial results for systemic lupus erythematosus (SLE) are propelling Roche closer to offering new hope for patients with this chronic condition, which currently has limited effective treatments. This success underscores the potential of targeted therapies in transforming treatment paradigms for autoimmune diseases.Eli Lilly's $3 billion investment in a new manufacturing facility in the Netherlands marks a strategic effort to bolster oral medicine production globally. This expansion not only reinforces Lilly's commitment to meeting global demand but also reflects an industry-wide trend towards investing in scalable manufacturing capabilities. Such moves are critical for ensuring supply chain resilience and addressing rising healthcare needs worldwide.In legal news, Pfizer's fierce competition with Metsera over Novo Nordisk's counteroffer highlights the high stakes involved in securing promising assets within the biotech sector—a sector particularly focused on obesity treatment due to its substantial market growth potential. The outcome of this legal battle could influence future strategic partnerships and acquisitions, demonstrating the intense competition among pharmaceutical giants.Meanwhile, UniQure faces challenges as its gene therapy for Huntington's disease encounters regulatory hurdles with the FDA. Despite initial expectations as a groundbreaking treatment, this setback emphasizes the rigorous scrutiny gene therapies undergo to ensure safety and efficacy. Such hurdles highlight the complexities of advancing novel therapies through regulatory pathways.Policy developments are also reshaping drug pricing structures as evidenced by HRSA's approval of eight drugmakers' plans for a 340B rebate model pilot program. This initiative aims at optimizing pricing structures while balancing cost containment with access to essential medications for underserved populations—a critical concern in today's healthcare landscape.International collaborations continue to play a pivotal role in accelerating drug discovery and development. Neurocrine Biosciences' $880 million deal with China's TransThera Sciences exemplifies such partnerships, focusing on emerging therapeutic areas like immunology. These collaborations are vital in leveraging global expertise and resources to drive innovatSupport the show

In this episode, Greg and Rob share initial reactions to the HRSA update on 340B rebate model implementation. They'll review the communication provided by HRSA on October 30th on their website, as well as discuss some of the manufacturer letters published on October 31st, that formally communicate rebate policies to 340B stakeholders.   HRSA 340B Rebate Website: https://www.hrsa.gov/opa/340b-model-pilot-program Beacon Manufacturer Resources Website (includes letters): https://cm.beaconchannelmanagement.com/pages/resources   Email us at 340BUnscripted@spendmend.com with questions, comments and topic suggestions!

Between new developments on a rebate pilot program, discussions of possible cuts to Medicare payment for 340B drugs, and new action in states nationwide, this fall has been a jam-packed season for 340B. We sit down with 340B Health President and CEO Maureen Testoni to break down the latest.Questions Remain About January's 340B Rebate Pilot After the Health Resources & Services Administration (HRSA) released 340B rebate pilot program guidance over the summer, all nine manufacturers of the 10 drugs subject to Medicare price caps applied to HRSA to implement rebates for the drugs starting in January. Testoni says we expect to find out which plans are approved in early November, as drugmakers need to give eight weeks of notice so covered entities can prepare for the change. Testoni says questions remain about the rebate pilot, but information that the drugmakers' rebate vendor has released so far provides enough detail for hospitals to start preparing for both rebates and price caps.Potential Medicare Cuts Expected To Target 340B HospitalsEarlier this year, the Trump administration released an executive order directing the Centers for Medicare & Medicaid Services (CMS) to survey hospitals on drug acquisition costs with the goal of using the results to set payment rates for Medicare Part B drugs starting in 2027. Testoni says she is concerned the proposed survey will lead to CMS targeting only 340B drugs for cuts that could bring payment rates down to actual acquisition costs, which would be a steeper cut than what the agency imposed during the first Trump administration.States Keep Moving on Contract Pharmacy Protections, 340B MandatesNearly 20 states have contract pharmacy protection laws in place and a small number of drugmakers have sued to block all these statutes. But Testoni says so far, courts have denied those requests and the laws have stayed in effect despite significant opposition advocacy by drugmakers. An increasing number of states also have enacted laws requiring 340B hospitals to report substantial data on their 340B costs and savings, and some are looking to limit how hospitals can use those savings.Resources:Senate Hearing Features Both Bipartisan Support for 340B and Calls for ReformsRead Our Comments on CBO's 340B Growth ReportReview Our 340B Rebate Pilot and IRA ResourcesBeacon Shares New Details on 340B Rebate Pilot Implementation

Rural Health News is a weekly segment of Rural Health Today, a podcast by Hillsdale Hospital. News sources for this episode: National Rural Health Association, “340B Drug Pricing Program & Pharmacy,” https://www.ruralhealth.us/advocacy/advocacy-priority-areas/340b-drug-pricing-program National Rural Health Association, “Rural 340B: NRHA Factsheet and Talking Points,” https://www.ruralhealth.us/nationalruralhealth/media/documents/advocacy/2025/rural-340b.pdf Michigan Health & Hospital Association, “340B Drug Discount Program.” https://www.mha.org/issues-advocacy/federal-issues/340b/ American Hospital Association, “Fact Sheet: The 340B Drug Pricing Program,” October 2025, https://www.aha.org/fact-sheets/fact-sheet-340b-drug-pricing-program Rural Health Today is a production of Hillsdale Hospital in Hillsdale, Michigan and a member of the Health Podcast Network. Our host is JJ Hodshire, our producer is Kyrsten Newlon, and our audio engineer is Kenji Ulmer. Special thanks to our special guests for sharing their expertise on the show, and also to the Hillsdale Hospital marketing team. If you want to submit a question for us to answer on the podcast or learn more about Rural Health Today, visit ruralhealthtoday.com.

America's hospitals will soon face an unprecedented rebate-based prescription drug model, come Jan. 1 – that's when there will be as many as 10 major drugs subject to Medicare price caps. This development is expected to create administrative and financial challenges for hospitals, which will have to pay the commercial price for such drugs while waiting for the rebates.For analysis and context, Maureen Testoni, president and CEO for 340B, will be the special guest during the next live edition of Monitor Monday. She will also review a recent Congressional Budget Office (CBO) report, featured in a recent Senate committee hearing, that includes some misrepresentations about why the 340B program has grown in recent years.As a special bonus, the longtime Internet broadcast produced by RACmonitor, will feature senior healthcare consultant Drew Updike, MD, who will recognize the tireless work being performed by the employees of the U.S. Department of Health and Human Services Office of Inspector General (HHS-OIG) who continue to work despite the federal shutdown, now in its fifth week.The weekly broadcast will also include these instantly recognizable features:Monday Rounds: Ronald Hirsch, MD, vice president of R1 RCM, will be making his Monday Rounds.The RAC Report: Healthcare attorney Knicole Emanuel, partner at the law firm of Nelson Mullins, will report the latest news about auditors.Risky Business: Healthcare attorney David Glaser, shareholder in the law offices of Fredrikson & Byron, will join the broadcast with his trademark segment.Legislative Update: Adam Brenman, senior legislative affairs analyst for Zelis, will report on the news happening at the intersection of healthcare and congressional action.

The fellas are reveling in the Democratic Party's absolute chaos, starting with the government shutdown. Anonymous Democratic senators confess they would vote to reopen the government but are "terrified of getting the guillotine" from the deranged grassroots—a direct admission that their base is driving the insanity. The Civil War's second front is a primary race for a chance to challenge Susan Collins in Maine, and it is a certified freak show. Chuck Schumer's establishment candidate, an ancient, unrelatable governor, is facing off against a Bernie bro who called himself an "Antifa super soldier." Maybe Graham Platner would get further in politics with less 1942 SS tattoos.  Secretary of the Army Dan Driscoll gives us a behind-the-scenes look at the aggressive, transformational change happening at the Army. Driscoll doesn't hold back, detailing the utter waste of taxpayer money caused by decades of calcified bureaucracy, like how the Army pays double for chicken because of an absurd 1930s mandate. He explains how he and the Chief of Staff are cutting $48 billion in expected spending to prioritize the modern warfighter, focusing on next-generation technology, and why President Trump's “peace through strength” approach and air cover have been vital to these efforts. 00:00 - Government Shutdown Drama: "Guillotine" Fear06:06 - Shutdown as Virginia Strategy09:50 - Merkley's 15-Hour Yawn-Fest & Katherine Clark's "Leeeverage" Gaffe16:10 - Maine Senate Primary: Nazi Tattoos, Antifa Soldiers, and the Establishment's Pick44:48 - King of the Hill: George Conway vs. Sarah Longwell58:33 - Secretary of the Army Dan DriscollOur Sponsors:➢Tell Republicans in Congress stop Dick Durbin's takeover of your credit card before it's too late - https://electronicpaymentscoalition.org/➢Big tax-exempt hospitals abuse the 340B markup program, tell congress to fix 340B.https://phrma.org/340Bmarkup➢Find out the true power of America's oil and natural gas. Go to https://lightsonenergy.org/➢The Partnership to Fight Chronic Disease wants to act sooner on Alzheimer's, not later. Learn more at https://www.pfcdalz.org/➢Want to make a difference in your community? https://takeonesmallstep.org/ Join AFP's grass-roots efforts at https://afpvolunteer.com/ Learn more about your ad choices. Visit podcastchoices.com/adchoices

In this week's Healthcare Preview podcast, Debbie Curtis and Rodney Whitlock join Erin Fuller to discuss the ongoing government shutdown and the upcoming Senate HELP Committee hearing on the 340B program.

Pink Sheet Executive Editor Derrick Gingery, Senior Writer Sarah Karlin-Smith and Editor-in-Chief Nielsen Hobbs discuss the reasons US Food and Drug Administration Commissioner Martin Makary could have helped negotiate the Most Favored Nation drug pricing deal with Astra Zeneca (:30) and the deal's potential impact on the 340B program (16:35). They also consider the Justice Department's alternative interpretation of off-label promotion regulations and the effect on the scientific exchange of information about drugs (19:16). More On These Topics From The Pink Sheet US FDA Commissioner's Involvement In AstraZeneca Pricing Deal Raises Ethical, Legal Questions: https://insights.citeline.com/pink-sheet/market-access/pricing-debate/us-fda-commissioners-involvement-in-astrazeneca-pricing-deal-raises-ethical-legal-questions-IJV4LMTDA5E65KCOFQUQM76GCA/ EMD Serono IVF Candidate Among First US FDA Priority Voucher Recipients As Part Of MFN Deal: https://insights.citeline.com/pink-sheet/market-access/pricing-debate/emd-serono-ivf-candidate-among-first-us-fda-priority-voucher-recipients-as-part-of-mfn-deal-LKHA6VRTKRE6DJERGNCWCGMBF4/ Manufacturer Most Favored Nation Deals: How They Could Be Protected From 340B: https://insights.citeline.com/pink-sheet/market-access/pricing-debate/manufacturer-most-favored-nation-deals-how-they-could-be-protected-from-340b-FALSG7GHM5GQBFN3I5SPERJIYU/ Off-Label Promotion: DOJ May Take New Look At Scientific Information Exchange: https://insights.citeline.com/pink-sheet/legalandip/litigation/off-label-promotion-doj-may-take-new-look-at-scientific-information-exchange-R62PQJFQTRBCVGCZE57GWM3Q3Q/

About two years ago, Indiana University Health implemented a 340B-funded comprehensive medication review clinic after pharmacy staff noticed patients at their hospitals were not filling maintenance prescriptions due to high cost. Although patient assistance was available, there was not a systematic approach to connecting qualifying patients with the financial help and education they needed, and the health system started the clinic to fill that gap. IU Health Regional Pharmacy Manager of Ambulatory Services Carrie Krekeler discusses how the clinic came about and how it works to improve patient health outcomes.Improved Drug Affordability and Patient EducationWhen a prescription goes through IU Health's comprehensive medication review clinic, pharmacists and other staff will prioritize finding financial assistance for eligible individuals and teaching patients important information about taking their medications. Krekeler says clinic staff will look for discounts for all medications a patient is on and see what a patient's insurance will cover, if there are copays, and if prior authorization is needed. Staff then will connect patients to coupon cards, manufacturer assistance programs, or 340B-funded assistance through IU Health.Demonstrated ResultsIn the two years since the clinic launched, Krekeler says its success has prompted IU Health to reinvest more 340B dollars to expand its reach. Patients with heart failure and diabetes who have gone through the clinic have seen significant improvements in their key health metrics. The clinic helps patients better maintain their health and stay out of the hospital.Understanding 340B Is Vital for Such ProgramsKrekeler says IU Health was able to launch its clinic after adapting a similar initiative that UC Davis had implemented. The key to getting the IU Health clinic off the ground was obtaining buy-in from executives who understood 340B and finance and were able to see the long-term benefit in investing 340B dollars in this area.

In this special RxBenefits-sponsored episode of The ASHHRA Podcast, hosts Bo Brabo and Luke Carignan explore the dynamic pharmacy benefits landscape with experts Sarah Hearn and Wes Hill (Director of Compliance & Legal Operations). Amid the busiest legislative season yet—over 1,500 bills—they discuss PBM reforms, ERISA challenges, compounding alternatives for GLP-1 drugs like Ozempic, 340B pricing, and emerging lawsuits. Gain insights on transparency, cost savings, and compliance for healthcare HR pros navigating employee benefits.Key takeaways for healthcare HR leaders:Legislative Surge: 1,500+ state bills target PBMs, carriers, and more; expect increased reporting burdens but better data for informed decisions.ERISA Erosion Risks: States challenge federal uniformity—multi-state plans face conflicting laws; monitor for compliance headaches.Positive Reforms: New mandates empower plan sponsors with PBM data; leverage 340B and coupons to cut costs (e.g., Wegovy from $1,000 to $100/month).Compounding & Innovation: Affordable GLP-1 alternatives via telehealth, but ensure safety and avoid controlled substance pitfalls.Lawsuits to Watch: Oklahoma ERISA win; Arkansas PBM permit ban challenges interstate commerce—outcomes could reshape operations.Action Steps: Demand vendor transparency; align with ERISA; educate teams on benefits to prevent misuse and optimize savings.Essential listening for HR managing rising pharmacy costs and regulations. Spark curiosity—reach out to RxBenefits for guidance!From Our Sponsors...Optimize Pharmacy Benefits with RxBenefitsElevate your employee benefits while managing costs. Did you know hospital employees fill 25% more prescriptions annually than other industries? Ensure cost-effective, high-quality pharmacy plans by leveraging your hospital's own pharmacies. Discover smarter strategies with RxBenefits.Learn More here - https://rxbene.fit/3ZaurZNStreamline HR Compliance with oneBADGEhealthcareSimplify screening, credentialing, and compliance for healthcare HR. oneBADGEhealthcare from ISB Global offers a tailored solution to keep your workforce compliant and efficient. Built for healthcare leaders, it's your all-in-one compliance tool.Get Started here - https://isbglobalservices.com/onebadgeunitedstates/ashhra/ Support the show

Originally broadcast October 9, 2025 $44 billion in drugs that help Americans are purchased through a little-known federal discount program called 340B. The program is recognized for successfully helping hospitals, community health centers and others that fund care for low-income patients.   But that program is now facing big challenges from drugmakers, and the current government shutdown has brought new uncertainty. Reporter William Newton of 340B Report tells hosts Mark Masselli and Margaret Flinter that the shutdown has delayed approvals... Read More Read More The post Government Shutdown Stalls Drug Discount Program 340B appeared first on Healthy Communities Online.

These may include stricter eligibility criteria, increased reporting requirements and potential reductions in reimbursement. 

In this episode, Greg and Rob are joined by SpendMend colleague Heather Lynch, to talk about how H.R.1 (i.e. One Big Beautiful Bill Act, or OBBBA) could impact 340B covered entities in the long run. They'll discuss how federal Medicaid cuts projected from the bill could influence a trend in lower average DSH% for some hospitals, threatening 340B Program eligibility. They'll also have a conversation about things hospitals should consider, both in the short term and long term, to brace for the impact. In the intro, they'll also catch up on various manufacturer actions affecting 340B providers. Email us at 340BUnscripted@spendmend.com with questions and comments!

In this episode, Jamie Leonard shares her journey from clinical pharmacist to Director of Pharmacy at Benefis Health System in Great Falls, Montana. She oversees pharmacy operations across the continuum of care, including acute care, cancer and infusion centers, long-term care, critical access hospitals, and Benefis' 340B program. Jamie discusses the unique challenges of serving a largely rural and government-payer-heavy population, while emphasizing Benefis' strong commitment to community health, education, and work-life balance. She highlights key pharmacy initiatives such as expanding specialty and retail pharmacy, growing a Meds-to-Beds program, and supporting patients with timely medication access—critical in a state where patients often travel long distances.

In this episode of DC EKG, host Joe Grogan is joined by Ryan Long, Capitol Hill veteran and senior research fellow at the Paragon Institute, to unpack two big health policy debates: the 340B drug discount program and the enhanced ACA premium tax credits. Ryan explains how 340B drives higher drug spending, hospital consolidation, and rising premiums, while often benefiting wealthier hospitals over safety-net providers. He also breaks down why the temporary ACA subsidies are set to expire in 2025, the fraud and enrollment issues they've created, and what both parties are gearing up for as the fight continues.

340B savings do not just enable hospitals to provide more care, they also help hospitals pioneer innovative approaches to bringing care directly to patients. For West Virginia University Medicine, which serves a high population of Medicare and Medicaid patients, one of these 340B-funded innovations came from recognizing a need to increase cancer screening rates. WVU Medicine 340B Enterprise Director Karen Famoso tells us how the system's mobile cancer screening initiative came about.The Barriers to Cancer ScreeningWVU Medicine identified that some of the biggest social determinants of health for its West Virginia patients were relatively unique to the areas it serves. The rural state has significant travel barriers, small population areas, and high poverty rates, a combination that leaves thousands of patients without easy access to a source of primary care.Mobile Screenings Look for Breast, Lung CancersToday, WVU Medicine operates two types of mobile cancer projects: Bonnie's Bus and LUCAS. The former launched in 2009 and is a mobile mammography unit named after a patient who died because she had limited access to breast cancer screenings. Her family donated funding to the hospital to support this effort. More than a decade later, WVU Medicine introduced the mobile lung screening program LUCAS. That initiative provides low-dose CT scans to patients meeting the screening guideline using a nearly 70,000-pound tractor trailer.340B Is Key To Sustaining Mobile Screening EffortsFamoso says WVU Medicine funds its mobile cancer screening programs through grants and donations, but that is not enough to cover the full cost. That is where 340B savings can help cover the operating loss, which was almost $400,000 last year. Without those 340B savings, the health system's financial situation would not allow investments in mission-focused programs such as Bonnie's Bus and LUCAS.ResourcesLung Cancer Screening on WheelsHRSA Reviewing Rebate Pilot Proposals and CommentsSecond Federal Appeals Court Upholds State Contract Pharmacy Law

In this episode, Laura Dyrda, Vice President and Editor-in-Chief at Becker's Healthcare, highlights critical policy debates around ACA subsidies, telehealth, hospital-at-home programs, and the future of the 340B program, sharing how these developments could impact hospitals, patients, and health system sustainability.

In this episode, Greg and Rob review recent changes made to the HRSA Audit Data Request List (DRL). They also discuss some of the comments provided by the public to HRSA regarding potential 340B rebate models, debate a recent change to a manufacturer's contract pharmacy restrictions, and highlight some communication that has gone out to hospitals regarding a proposed CMS 340B drug acquisition cost survey expected in CY26. SpendMend's comments on HRSA's proposed 340B rebate model: https://www.regulations.gov/comment/HRSA-2025-0001-1115 CMS proposed Medicare Part B 340B drug acquisition cost survey template: CMS-10931 | CMS   Got questions? Email us at 340BUnscripted@spendmend.com 

In this episode, Eric Huckins, Vice President of Business Development at Lumicera Health Services, discusses how health systems can build stronger specialty pharmacy programs by navigating challenges such as 340B, payer access, and accreditation. He also highlights the role of strategic partnerships, biosimilars, and technology in improving patient care and driving growth.This episode was sponsored by Lumicera Health Services.

One important but understated aspect of 340B compliance is the importance of training new and existing team members on how the program works. But what does effective training look like? Pooja Shah, the system pharmacy manager of 340B programs at University of North Carolina Health, walks us through the key elements of an effective and engaging 340B education strategy.Setting a Baseline of 340B KnowledgeUNC Health utilizes a two-pronged strategy to 340B education for its team: didactic and interactive approaches. The didactic approach involves creating three online, standardized learning modules to educate those who are new to 340B or who interact with it indirectly as well as those who are more involved in day-to-day 340B operations. The interactive approach involves an educational and decision-making structure designed to adapt to new 340B developments in real time. Compliance Meetings Facilitate DiscussionUNC Health uses entity-level and system-level oversight committees to discuss key 340B compliance issues and relevant metrics. Shah says these meetings offer ways to inform senior leadership about key 340B changes and keep other stakeholders, such as hospital compliance and legal credentialing professionals, in the loop.340B Education Is Best When NimbleAs hospitals evaluate their 340B education efforts, Shah says it's important they explore existing resources but also work with stakeholders to discuss what would best serve them when learning about 340B. Hospitals also can change existing governance structures to incorporate 340B discussions. Shah says the ability to stay nimble and be able to quickly identify and assemble key players in the 340B space is key to keeping teams informed amid times of change.ResourcesRead Our Appeals Court Brief Opposing 340B Rebate Schemes

In this episode, Greg and Rob catch up on insights gathered and lessons learned from various forums our team has attended over the last few weeks. Also, they discuss the recently posted FAQ page provided by HRSA in response to questions around the 340B Rebate Model Pilot Program. 340B Rebate HRSA FAQ: https://www.hrsa.gov/opa/340b-model-pilot-program 340B Rebate Comments: https://www.regulations.gov/document/HRSA-2025-0001-0001

One in four Americans is enrolled in Medicaid, yet the system designed to support them is constantly at risk—underfunded, politically vulnerable, and often overlooked.Dr. Alastair Bell, President and CEO of Boston Medical Center Health System, shares how his organization is reimagining what it means to care for underserved populations, while managing nearly 40% of Massachusetts' Medicaid enrollees. In this conversation, we explore the financial realities of running an “essential” hospital system, the opportunities and pitfalls of Medicaid ACOs, and why AI might deepen inequity if essential providers are left behind.We cover:

In this episode, Greg and Rob discuss tips for completing the annual 340B hospital recertification process, which is occurring now through early September. They also recap a recent notice in the Federal Register that signals HRSA's intent on modifying some elements of OPAIS and the 340B enrollment/registration/recertification process. The guys also can't help themselves and wrap up with another debate around impending 340B rebate considerations. Proposed OPAIS changes: https://www.federalregister.gov/documents/2025/08/07/2025-14955/agency-information-collection-activities-proposed-collection-public-comment-request-information   Register for our Trulla webinar on August 26th: https://attendee.gotowebinar.com/register/2844398547415085144?source=340B+Unscripted

Dr. Anthony DiGiorgio, a neurosurgeon at UCSF with a strong interest in healthcare policy, joins the show to unpack the complex and often misunderstood world of Medicaid. In a wide-ranging and nuanced discussion, he explores who qualifies for coverage, why most Medicaid spending goes to groups people don't typically expect, and whether the system should be expanded or fundamentally reformed. Dr. DiGiorgio outlines his support for a robust safety net, emphasizing targeted subsidies over a government-run program, and offers his take on the proposed “Big Beautiful Bill” currently in Congress. Along the way, the conversation touches on broader healthcare issues including the 340B drug discount program, the Affordable Care Act, and the role of the free market in ensuring access to care. Check out Chadi's website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

This episode features Paige Twenter, Assistant Editor at Becker's Hospital Review, as she discusses key healthcare policy developments including restrictions on gender-affirming care, federal pressure on pharmaceutical companies to lower U.S. drug prices, and major changes to the 340B drug pricing program.